APA

Miknyoczki S., Chang H., Grobelny J., Pritchard S., Worrell C., McGann N., Ator M., Husten J., Deibold J., Hudkins R., Zulli A., Parchment R. & Ruggeri B. (20071015). The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. : Molecular cancer therapeutics.

Chicago

Miknyoczki Sheila, Chang Hong, Grobelny Jennifer, Pritchard Sonya, Worrell Candace, McGann Natalie, Ator Mark, Husten Jean, Deibold James, Hudkins Robert, Zulli Allison, Parchment Ralph and Ruggeri Bruce. 20071015. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. : Molecular cancer therapeutics.

Harvard

Miknyoczki S., Chang H., Grobelny J., Pritchard S., Worrell C., McGann N., Ator M., Husten J., Deibold J., Hudkins R., Zulli A., Parchment R. and Ruggeri B. (20071015). The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. : Molecular cancer therapeutics.

MLA

Miknyoczki Sheila, Chang Hong, Grobelny Jennifer, Pritchard Sonya, Worrell Candace, McGann Natalie, Ator Mark, Husten Jean, Deibold James, Hudkins Robert, Zulli Allison, Parchment Ralph and Ruggeri Bruce. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. : Molecular cancer therapeutics. 20071015.